Treatment of Peyronie's disease with verapamil

Abstract

Background and Design.- Multifile oral or topi¬cal agents have been used in "the treatment of-Peyronie's disease. Responses have not been satisfac¬tory. Verapamil is a calcium channel blocker which can alter the metabolism of fibroblasts. It has been used to decrease fibroblastic activity in the tunica albuginea of the penis. In.this nonrandomized study, a group of 27 previously untreated men with Peyronie's disease received biweekly injections of ver¬apamil intralesionally for 6 months. Results.- Subjective improvement in curvature (25%) and pain (85%) was significant. Objectively, decreased plaque volume of 50% or more was noted in 43.5% of the patients. Ease "of injection into plaque was noted in 80% of the patients during the treatment. Erectile status was better in 35% of the patients. Conclusion.-Although this nonrandomized study shows that intralesional verapamil injection is promis¬ing in Peyronie's disease, prospective double-blind clinical studies will determine its ultimate usefulness.